Healthcare provider profile · identity verified

David Thomas Ade, MD

Allopathic & Osteopathic Physicians|Internal Medicine · MOLINE, IL · NPI 1972589042

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show David Thomas Ade, MD received $39.19 in general payments during 2025 across 3 reported records.

AstraZeneca Pharmaceuticals LP accounted for 43.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$39.19

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$16.87	43.0%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$15.39	39.3%	1	2025
Echosens North America, Inc.	Unresolved — no canonical attribution shown	$6.93	17.7%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$39.19	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
BREZTRI Normalized: breztri	Drug	AstraZeneca Pharmaceuticals LP	$16.87	1	2025
Source payment records 2025-11-25 · AstraZeneca Pharmaceuticals LP · $16.87 · Open Payments source
SHINGRIX Normalized: shingrix	Biological	GlaxoSmithKline, LLC.	$15.39	1	2025
Source payment records 2025-09-17 · GlaxoSmithKline, LLC. · $15.39 · Open Payments source
Fibroscan Normalized: fibroscan	Device	Echosens North America, Inc.	$6.93	1	2025
Source payment records 2025-08-26 · Echosens North America, Inc. · $6.93 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	75	22

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	920	239
Atorvastatin Calcium	Atorvastatin Calcium	732	200
Amlodipine Besylate	Amlodipine Besylate	656	191
Furosemide	Furosemide	614	167
Lisinopril	Lisinopril	554	154
Simvastatin	Simvastatin	544	143
Losartan Potassium	Losartan Potassium	472	134
Pantoprazole Sodium	Pantoprazole Sodium	469	139
Metoprolol Succinate	Metoprolol Succinate	447	133
Gabapentin	Gabapentin	431	111
Omeprazole	Omeprazole	425	107
Meloxicam	Meloxicam	398	109
Metformin Hcl	Metformin Hcl	362	104
Lorazepam	Lorazepam	361	71
Tamsulosin Hcl	Tamsulosin Hcl	338	94
Zolpidem Tartrate	Zolpidem Tartrate	321	55
Glipizide	Glipizide	308	79
Albuterol Sulfate Hfa	Albuterol Sulfate	292	114
Pravastatin Sodium	Pravastatin Sodium	289	79
Trazodone Hcl	Trazodone Hcl	277	56
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	274	89
Alprazolam	Alprazolam	272	42
Potassium Chloride	Potassium Chloride	271	81
Rosuvastatin Calcium	Rosuvastatin Calcium	261	84
Sertraline Hcl	Sertraline Hcl	250	55
Montelukast Sodium	Montelukast Sodium	249	68
Vitamin D2	Ergocalciferol (Vitamin D2)	247	76
Metoprolol Tartrate	Metoprolol Tartrate	238	64
Prednisone	Prednisone	227	154
Eliquis	Apixaban	211	51
Ibuprofen	Ibuprofen	211	62
Nabumetone	Nabumetone	194	44
Azithromycin	Azithromycin	183	127
Fluoxetine Hcl	Fluoxetine Hcl	177	53
Levofloxacin	Levofloxacin	177	126
Clopidogrel	Clopidogrel Bisulfate	176	45
Carvedilol	Carvedilol	160	51
Duloxetine Hcl	Duloxetine Hcl	159	38
Hydrochlorothiazide	Hydrochlorothiazide	159	53
Allopurinol	Allopurinol	158	48
Amoxicillin	Amoxicillin	154	110
Atenolol	Atenolol	148	44
Doxycycline Hyclate	Doxycycline Hyclate	147	105
Ezetimibe	Ezetimibe	144	38
Meclizine Hcl	Meclizine Hcl	142	46
Famotidine	Famotidine	134	31
Escitalopram Oxalate	Escitalopram Oxalate	127	34
Glipizide Er	Glipizide	127	41
Irbesartan	Irbesartan	127	33
Triamcinolone Acetonide	Triamcinolone Acetonide	117	82
Ipratropium Bromide	Ipratropium Bromide	114	40
Fluticasone Propionate	Fluticasone Propionate	109	37
Temazepam	Temazepam	107	18
Cephalexin	Cephalexin	106	87
Donepezil Hcl	Donepezil Hcl	106	33
Quetiapine Fumarate	Quetiapine Fumarate	103	15
Clonidine Hcl	Clonidine Hcl	100	26
Jardiance	Empagliflozin	95	25
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	92	24
Warfarin Sodium	Warfarin Sodium	90	17
Ropinirole Hcl	Ropinirole Hcl	81	22
Clonazepam	Clonazepam	79	12
Celecoxib	Celecoxib	75	15
Nifedipine Er	Nifedipine	75	24
Spironolactone	Spironolactone	75	18
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	75	22
Paroxetine Hcl	Paroxetine Hcl	73	13
Pioglitazone Hcl	Pioglitazone Hcl	73	22
Sildenafil Citrate	Sildenafil Citrate	70	11
Hydroxyzine Hcl	Hydroxyzine Hcl	68	27
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	64	suppressed
Naproxen	Naproxen	64	18
Oxybutynin Chloride Er	Oxybutynin Chloride	63	23
Hydralazine Hcl	Hydralazine Hcl	61	20
Levetiracetam	Levetiracetam	61	suppressed
Lovastatin	Lovastatin	60	16
Memantine Hcl	Memantine Hcl	60	12
Amitriptyline Hcl	Amitriptyline Hcl	59	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	17
Metformin Hcl Er	Metformin Hcl	57	19
Myrbetriq	Mirabegron	57	13
Oxybutynin Chloride	Oxybutynin Chloride	57	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	56	16
Dutasteride	Dutasteride	55	17
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	53	12
Doxazosin Mesylate	Doxazosin Mesylate	51	12
Dicyclomine Hcl	Dicyclomine Hcl	50	13
Sumatriptan Succinate	Sumatriptan Succinate	50	17
Synthroid	Levothyroxine Sodium	50	11
Aripiprazole	Aripiprazole	49	suppressed
Enalapril Maleate	Enalapril Maleate	48	14
Methylprednisolone	Methylprednisolone	48	30
Nystatin	Nystatin	48	31
Diazepam	Diazepam	47	suppressed
Terbinafine Hcl	Terbinafine Hcl	47	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	46	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	45	17
Olmesartan Medoxomil	Olmesartan Medoxomil	45	16
Finasteride	Finasteride	44	14
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	44	38
Ondansetron Odt	Ondansetron	44	26
Ozempic	Semaglutide	44	15
Propranolol Hcl	Propranolol Hcl	44	suppressed
Xarelto	Rivaroxaban	44	suppressed
Citalopram Hbr	Citalopram Hydrobromide	43	12
Digoxin	Digoxin	42	suppressed
Sucralfate	Sucralfate	42	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	41	34
Baclofen	Baclofen	41	11
Fluconazole	Fluconazole	41	30
Metolazone	Metolazone	41	suppressed
Ventolin Hfa	Albuterol Sulfate	40	11
Alendronate Sodium	Alendronate Sodium	39	suppressed
Glimepiride	Glimepiride	38	17
Ondansetron Hcl	Ondansetron Hcl	38	30
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	38	27
Cholestyramine	Cholestyramine (With Sugar)	37	suppressed
Klor-Con M20	Potassium Chloride	37	15
Isosorbide Mononitrate Er	Isosorbide Mononitrate	36	suppressed
Valacyclovir	Valacyclovir Hcl	35	14
Verapamil Er	Verapamil Hcl	35	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	34	23
Nitroglycerin	Nitroglycerin	34	25
Pregabalin	Pregabalin	34	suppressed
Doxepin Hcl	Doxepin Hcl	33	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	32	13
Farxiga	Dapagliflozin Propanediol	31	suppressed
Januvia	Sitagliptin Phosphate	31	suppressed
Eszopiclone	Eszopiclone	30	suppressed
Midodrine Hcl	Midodrine Hcl	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Colesevelam Hcl	Colesevelam Hcl	28	suppressed
Methotrexate	Methotrexate Sodium	28	suppressed
Valsartan	Valsartan	27	suppressed
Gemfibrozil	Gemfibrozil	26	suppressed
Pyridostigmine Bromide	Pyridostigmine Bromide	26	suppressed
Symbicort	Budesonide/Formoterol Fumarate	26	suppressed
Entresto	Sacubitril/Valsartan	25	suppressed
Lubiprostone	Lubiprostone	25	11
Metoclopramide Hcl	Metoclopramide Hcl	24	suppressed
Hydrocortisone	Hydrocortisone	23	suppressed
Mupirocin	Mupirocin	23	15
Prochlorperazine Maleate	Prochlorperazine Maleate	23	14
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Acyclovir	Acyclovir	21	suppressed
Cefuroxime	Cefuroxime Axetil	21	19
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	17
Varenicline Tartrate	Varenicline Tartrate	21	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	20	17
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Nystop	Nystatin	20	13
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Bumetanide	Bumetanide	19	suppressed
Estradiol	Estradiol	19	suppressed
Megestrol Acetate	Megestrol Acetate	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Primidone	Primidone	19	suppressed
Torsemide	Torsemide	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	18	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	17	suppressed
Ibandronate Sodium	Ibandronate Sodium	17	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Nitroglycerin Patch	Nitroglycerin	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	11
Ibu	Ibuprofen	16	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	15	suppressed
Diltiazem Hcl	Diltiazem Hcl	15	suppressed
Levemir Flexpen	Insulin Detemir	15	suppressed
Linzess	Linaclotide	15	suppressed
Moxifloxacin	Moxifloxacin Hcl	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	14	suppressed
Amiloride-Hydrochlorothiazide	Amiloride/Hydrochlorothiazide	14	suppressed
Carisoprodol	Carisoprodol	14	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	14
Metronidazole	Metronidazole	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Famciclovir	Famciclovir	13	suppressed
Ssd	Silver Sulfadiazine	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Colestipol Hcl	Colestipol Hcl	12	suppressed
Eletriptan Hbr	Eletriptan Hydrobromide	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Ursodiol	Ursodiol	12	suppressed
Xanax	Alprazolam	12	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	12	suppressed
Indomethacin	Indomethacin	11	suppressed
Multaq	Dronedarone Hcl	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Naratriptan Hcl	Naratriptan Hcl	11	suppressed
Oxaprozin	Oxaprozin	11	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	11	suppressed
Testosterone Cypionate	Testosterone Cypionate	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	11
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed
Xeljanz Xr	Tofacitinib Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$39.19 · 3 records	AstraZeneca Pharmaceuticals LP	BREZTRI, Fibroscan, SHINGRIX	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error